Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women
Completed
Radius Health, Inc.
Phase 3
2011-04-01
The purpose of this study is to determine whether BA058 (abaloparatide), a parathyroid
hormone-related peptide, is effective in preventing fractures in postmenopausal women with
severe osteoporosis who are at risk of fractures.
Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis
Completed
Nordic Bioscience A/S
Phase 2
2012-09-25
To determine the clinical safety and efficacy of abaloparatide transdermal in otherwise
healthy postmenopausal women with osteoporosis as assessed by changes in bone mineral density
(BMD) and serum markers of bone metabolism when compared to transdermal placebo and
abaloparatide injection for 6 months of treatment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
